Cargando…

Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position

A series of chalcones substituted by a quinoxaline unit at the B-ring were synthesized and tested as inhibitors of breast cancer resistance protein-mediated mitoxantrone efflux. These compounds appeared more efficient than analogs containing other B-ring substituents such as 2-naphthyl or 3,4-methyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Winter, Evelyn, Gozzi, Gustavo Jabor, Chiaradia-Delatorre, Louise Domeneghini, Daflon-Yunes, Nathalia, Terreux, Raphael, Gauthier, Charlotte, Mascarello, Alessandra, Leal, Paulo César, Cadena, Silvia M, Yunes, Rosendo Augusto, Nunes, Ricardo José, Creczynski-Pasa, Tania Beatriz, Di Pietro, Attilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043709/
https://www.ncbi.nlm.nih.gov/pubmed/24920885
http://dx.doi.org/10.2147/DDDT.S56625
_version_ 1782318970632667136
author Winter, Evelyn
Gozzi, Gustavo Jabor
Chiaradia-Delatorre, Louise Domeneghini
Daflon-Yunes, Nathalia
Terreux, Raphael
Gauthier, Charlotte
Mascarello, Alessandra
Leal, Paulo César
Cadena, Silvia M
Yunes, Rosendo Augusto
Nunes, Ricardo José
Creczynski-Pasa, Tania Beatriz
Di Pietro, Attilio
author_facet Winter, Evelyn
Gozzi, Gustavo Jabor
Chiaradia-Delatorre, Louise Domeneghini
Daflon-Yunes, Nathalia
Terreux, Raphael
Gauthier, Charlotte
Mascarello, Alessandra
Leal, Paulo César
Cadena, Silvia M
Yunes, Rosendo Augusto
Nunes, Ricardo José
Creczynski-Pasa, Tania Beatriz
Di Pietro, Attilio
author_sort Winter, Evelyn
collection PubMed
description A series of chalcones substituted by a quinoxaline unit at the B-ring were synthesized and tested as inhibitors of breast cancer resistance protein-mediated mitoxantrone efflux. These compounds appeared more efficient than analogs containing other B-ring substituents such as 2-naphthyl or 3,4-methylenedioxyphenyl while an intermediate inhibitory activity was obtained with a 1-naphthyl group. In all cases, two or three methoxy groups had to be present on the phenyl A-ring to produce a maximal inhibition. Molecular modeling indicated both electrostatic and steric positive contributions. A higher potency was observed when the 2-naphthyl or 3,4-methylenedioxyphenyl group was shifted to the A-ring and methoxy substituents were shifted to the phenyl B-ring, indicating preferences among polyspecificity of inhibition.
format Online
Article
Text
id pubmed-4043709
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-40437092014-06-11 Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position Winter, Evelyn Gozzi, Gustavo Jabor Chiaradia-Delatorre, Louise Domeneghini Daflon-Yunes, Nathalia Terreux, Raphael Gauthier, Charlotte Mascarello, Alessandra Leal, Paulo César Cadena, Silvia M Yunes, Rosendo Augusto Nunes, Ricardo José Creczynski-Pasa, Tania Beatriz Di Pietro, Attilio Drug Des Devel Ther Original Research A series of chalcones substituted by a quinoxaline unit at the B-ring were synthesized and tested as inhibitors of breast cancer resistance protein-mediated mitoxantrone efflux. These compounds appeared more efficient than analogs containing other B-ring substituents such as 2-naphthyl or 3,4-methylenedioxyphenyl while an intermediate inhibitory activity was obtained with a 1-naphthyl group. In all cases, two or three methoxy groups had to be present on the phenyl A-ring to produce a maximal inhibition. Molecular modeling indicated both electrostatic and steric positive contributions. A higher potency was observed when the 2-naphthyl or 3,4-methylenedioxyphenyl group was shifted to the A-ring and methoxy substituents were shifted to the phenyl B-ring, indicating preferences among polyspecificity of inhibition. Dove Medical Press 2014-05-27 /pmc/articles/PMC4043709/ /pubmed/24920885 http://dx.doi.org/10.2147/DDDT.S56625 Text en © 2014 Winter et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Winter, Evelyn
Gozzi, Gustavo Jabor
Chiaradia-Delatorre, Louise Domeneghini
Daflon-Yunes, Nathalia
Terreux, Raphael
Gauthier, Charlotte
Mascarello, Alessandra
Leal, Paulo César
Cadena, Silvia M
Yunes, Rosendo Augusto
Nunes, Ricardo José
Creczynski-Pasa, Tania Beatriz
Di Pietro, Attilio
Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position
title Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position
title_full Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position
title_fullStr Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position
title_full_unstemmed Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position
title_short Quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein ABCG2: polyspecificity at B-ring position
title_sort quinoxaline-substituted chalcones as new inhibitors of breast cancer resistance protein abcg2: polyspecificity at b-ring position
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043709/
https://www.ncbi.nlm.nih.gov/pubmed/24920885
http://dx.doi.org/10.2147/DDDT.S56625
work_keys_str_mv AT winterevelyn quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition
AT gozzigustavojabor quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition
AT chiaradiadelatorrelouisedomeneghini quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition
AT daflonyunesnathalia quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition
AT terreuxraphael quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition
AT gauthiercharlotte quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition
AT mascarelloalessandra quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition
AT lealpaulocesar quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition
AT cadenasilviam quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition
AT yunesrosendoaugusto quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition
AT nunesricardojose quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition
AT creczynskipasataniabeatriz quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition
AT dipietroattilio quinoxalinesubstitutedchalconesasnewinhibitorsofbreastcancerresistanceproteinabcg2polyspecificityatbringposition